Delve Bio, Inc., a Boston-based molecular diagnostics company originating from research at the University of California, San Francisco, announced on October 14, 2026, the commercial introduction of Delve Detect Plasma, a metagenomic next-generation sequencing test designed to identify infectious pathogens using a single blood sample. The service analyzes both DNA and RNA and compares sequencing results with a curated database covering more than 68,000 bacterial, viral, fungal and parasitic organisms, with results expected the day after the laboratory receives the specimen.
The launch expands Delve Bio’s testing portfolio beyond cerebrospinal fluid, where its existing Delve Detect service has been used to investigate suspected meningitis, encephalitis and other difficult central nervous system infections. Plasma testing offers a more accessible sampling route for patients with suspected systemic infections, particularly when conventional diagnostic investigations have not identified the cause. The company will introduce the new service at IDWeek 2026, scheduled for October 21 through October 24 in Washington, DC.
Delve Detect Plasma uses the company’s Delve Decide analysis technology and is performed through a laboratory certified under the Clinical Laboratory Improvement Amendments and accredited by the College of American Pathologists. However, the announcement does not provide plasma-specific clinical sensitivity, specificity or comparative detection rates. Its database coverage of more than 68,000 organisms represents the breadth of reference sequences available for analysis, not evidence that the assay has been individually validated against every listed pathogen.
The commercial development comes as healthcare providers increasingly evaluate broad molecular sequencing for patients with complex infections, unusual exposures or compromised immune systems. The central question is whether the plasma test can translate extensive sequencing coverage into reliable, clinically actionable diagnoses quickly enough to influence treatment decisions.
How does Delve Detect Plasma search for pathogens without requiring a suspected diagnosis?
Conventional infectious disease testing frequently depends on identifying a likely pathogen before choosing the appropriate test. Physicians may order bacterial cultures, targeted polymerase chain reaction assays, antibody tests or antigen detection methods according to the patient’s symptoms, medical history and potential exposure. These approaches can be highly effective when the likely cause is understood, but more complicated cases may require several rounds of testing.
Metagenomic next-generation sequencing takes a broader approach by analyzing genetic material present in a clinical sample. The process generates sequencing data that can be compared with reference sequences from different microorganisms, helping identify organisms that were not originally suspected. This can be particularly useful when patients have unusual presentations or when standard investigations provide inconclusive findings.
Delve Detect Plasma analyzes both DNA and RNA, an important distinction because clinically significant pathogens include organisms with different genetic structures. Some sequencing services focus on microbial cell-free DNA circulating in blood, whereas Delve’s announced approach includes analysis of RNA-associated pathogens. That broader analytical design may create opportunities to investigate infections involving RNA viruses alongside bacteria, fungi, parasites and DNA viruses.
However, the presence of a microbial sequence does not automatically establish that an organism is responsible for the patient’s illness. Findings must be interpreted according to the quantity and quality of sequencing evidence, potential contamination, clinical presentation and other laboratory results. Distinguishing true infection from incidental microbial material is an essential component of responsible metagenomic testing.
Delve Bio supplements its computational analysis with access to a Clinical Microbial Sequencing Board involving infectious disease and laboratory medicine specialists. This service is intended to help physicians interpret complicated findings within the patient’s clinical context. Its practical value will depend on whether the additional information changes diagnosis or management appropriately.
What does the database of more than 68,000 pathogens actually establish?
The reference database is a defining feature of the newly announced plasma service. Delve Bio says its curated collection covers more than 68,000 bacterial, fungal, viral and parasitic organisms, providing a broad resource for matching sequencing reads against microbial genetic information. This can help investigators consider organisms that may not be covered by conventional targeted diagnostic panels.
The figure should not be interpreted as a claim that the test can reliably diagnose every organism represented in the database. Analytical detection depends on the quantity of pathogen-derived material in the specimen, sequencing depth, genetic similarity between organisms and the performance of the laboratory’s analytical methods. Some organisms may also be difficult to identify accurately at the species or strain level.
A broad search creates challenges involving background signals and false-positive findings. Microbial sequences may originate from environmental contamination, specimen handling or organisms that are not causing clinically significant disease. Computational filtering and expert interpretation are therefore necessary to determine which results warrant attention.
False-negative results are also possible because a pathogen may not release detectable genetic material into plasma at the time of sampling. Infection confined primarily to a particular organ or compartment may produce little circulating material. The absence of a detected organism should therefore not be treated as definitive exclusion of infection when clinical suspicion remains substantial.
For healthcare organizations considering the test, analytical breadth is one part of the evaluation. Sensitivity, specificity, reproducibility, clinical utility and cost will determine whether the expanded reference database offers measurable advantages over existing diagnostic strategies.
What evidence from Delve Bio’s cerebrospinal-fluid test supports the platform?
The most substantial peer-reviewed evidence relevant to Delve Bio’s earlier technology comes from a study published in Nature Medicine in 2024. Researchers examined seven years of clinical metagenomic testing involving 4,828 cerebrospinal-fluid samples analyzed through the University of California, San Francisco clinical microbiology laboratory between June 2016 and April 2023. The study provides an important foundation for understanding the diagnostic capabilities and limitations of broad sequencing.
Across the full sample population, testing identified 797 organisms in 697 samples, equivalent to a positive detection rate of approximately 14.4%. The detected organisms included DNA viruses, RNA viruses, bacteria, fungi and parasites. This demonstrates the diversity of microorganisms that can be identified through comprehensive sequencing in a neurological infection setting.
A more detailed clinical analysis involved 1,164 samples from 1,053 patients. Among 220 infectious diagnoses in that subset, metagenomic sequencing was the only method identifying the diagnosis in 48 cases, representing approximately 21.8%. This finding illustrates how broad sequencing may contribute additional diagnostic information when conventional testing is incomplete.
The reported clinical sensitivity was 63.1%, while specificity reached 99.6%, with overall accuracy of 92.9%. These figures show that the technology can identify important infections with high specificity, but it does not detect every clinically established infection. Its performance must therefore be understood as complementary to other diagnostic methods rather than a universal replacement.
Crucially, these figures relate to cerebrospinal-fluid testing and cannot be transferred directly to Delve Detect Plasma. Blood and cerebrospinal fluid have different biological characteristics, pathogen concentrations and sources of background genetic material. The new plasma service requires its own evidence to establish diagnostic accuracy across intended clinical applications.
Why could plasma testing help patients with complex or unexplained infections?
Plasma samples can generally be obtained through a routine blood draw, making collection less invasive than lumbar puncture or tissue biopsy. This creates potential opportunities for investigating systemic infection when obtaining a sample directly from the affected organ is difficult or unsafe. It may be particularly relevant in patients with impaired immune function or infections involving multiple possible anatomical sites.
Immunocompromised patients can develop infections caused by uncommon microorganisms and may exhibit symptoms that differ from those typically encountered in otherwise healthy individuals. Their diagnostic workups can involve multiple laboratory tests, imaging investigations and sometimes invasive procedures. Broad sequencing could help physicians investigate a wider range of causes without selecting a separate initial assay for every suspected organism.
The test may also be useful when prior antimicrobial treatment has reduced the likelihood of successful culture. Molecular methods can detect microbial genetic material even when organisms are no longer readily recovered through conventional culture. However, this characteristic introduces an interpretive limitation because detectable genetic material does not necessarily indicate ongoing viable infection.
For critically ill patients, rapid diagnosis can affect the selection and duration of antimicrobial treatment. Identifying a specific cause may allow physicians to narrow treatment, investigate unusual pathogens or reconsider an infectious diagnosis. Nevertheless, the October launch announcement does not establish that Delve Detect Plasma reduces hospital mortality, antibiotic consumption or length of stay.
Those outcomes require clinical utility studies that measure how frequently test results change management and whether those changes improve care. The clinical importance of a diagnostic service ultimately depends on the decisions it enables, not simply the number of possible organisms it can recognize.
How meaningful is the promise of results the day after sample receipt?
Delve Bio says Delve Detect Plasma can provide results the day after a specimen arrives at its laboratory. That timetable could be valuable in situations where clinicians are waiting for evidence that may help guide treatment. However, the company’s promised turnaround begins at specimen receipt rather than the time a physician orders the test or collects blood.
Total diagnostic time will also depend on packaging, specimen preparation, transportation schedules, laboratory workflow and communication of the findings. A sample collected at a distant hospital may require additional time to reach the processing facility. The company has not disclosed a nationwide study measuring the complete interval from clinical order to actionable result.
The distinction matters when comparing next-day sequencing with other diagnostic approaches. Some targeted molecular assays can produce results within hours, particularly when performed in a hospital laboratory. Others, including specialist cultures and reference laboratory investigations, may require considerably longer.
Metagenomic testing may therefore be most valuable when conventional investigations would require numerous separate assays or when the likely pathogen is uncertain. It is not necessarily the fastest approach for a common infection that can already be diagnosed through an appropriate rapid test.
The service’s clinical usefulness will also depend on when physicians choose to order it. Earlier use may help avoid prolonged diagnostic uncertainty in selected patients, while indiscriminate testing could produce unnecessary costs or findings that complicate management.
What will Delve Bio present at IDWeek 2026?
Delve Bio and its scientific collaborators plan three research presentations during the IDWeek conference. Two posters scheduled for October 22 address neuroinvasive arbovirus infections and metagenomic subtyping of enteroviruses associated with meningoencephalitis. A third presentation on October 24 concerns detection of neurotropic astrovirus VA strains in immunocompromised patients.
The research illustrates applications of broad sequencing for microorganisms that may be difficult to identify through routine clinical testing. Viral infections involving the central nervous system can present with overlapping neurological symptoms, creating challenges when the specific cause is not immediately apparent. Metagenomic sequencing may help identify unexpected organisms or provide genomic information relevant to classification.
However, the three presentations primarily concern neurological infections and earlier metagenomic applications. They should not be described as a completed prospective validation study of the newly introduced plasma assay. The company has not disclosed numerical plasma sensitivity or specificity findings as part of the announced conference programme.
The meeting also provides a commercial introduction opportunity. Delve Bio will engage infectious disease specialists, clinical microbiologists and hospital decision-makers who may be interested in incorporating plasma metagenomic testing into diagnostic workflows. The success of that effort will depend on evidence quality and the ability to demonstrate when broad sequencing adds value.
What regulatory and reimbursement questions remain for Delve Detect Plasma?
Delve Bio states that its assays are performed in a CLIA-certified and CAP-accredited laboratory. These credentials establish an important laboratory quality framework, but they do not mean that the FDA has reviewed and cleared the new plasma assay’s clinical performance. The October announcement does not identify an FDA authorization specific to Delve Detect Plasma.
Laboratory-developed testing can be made available through qualifying clinical laboratory operations under the applicable regulatory framework. However, laboratories and physicians still need to understand the extent of validation, intended use and limitations of each assay. The availability of a service should not be equated with a regulator’s determination that it improves patient outcomes.
Reimbursement will also influence adoption. Hospitals and insurers may consider whether testing is medically necessary, how it compares with established investigations and whether its results lead to meaningful treatment changes. The announcement does not disclose a new national coverage determination, fixed reimbursement rate or published price for the plasma service.
Another commercial consideration is the cost of comprehensive sequencing relative to narrower testing strategies. A broad assay may reduce the need for multiple investigations in selected patients, but it may be less economical when the likely pathogen can be identified through a cheaper established method. Evidence connecting testing strategy to total healthcare expenditure will therefore be relevant.
Delve Bio’s earlier work in neurological infections provides a scientific starting point, but the company must establish the performance and clinical utility of the plasma service independently. The new test offers access to a broader specimen type and the ability to investigate both DNA and RNA organisms, which could be useful in complex infectious disease care.
The decisive next step will be publication of plasma-specific validation and real-world clinical results demonstrating when the expanded test improves diagnosis or treatment decisions. Until those data are available, Delve Detect Plasma should be understood as a newly launched broad sequencing service with a promising analytical approach rather than a clinically proven replacement for conventional infectious disease testing.
